The case had been filed last year by Amgen after the state Prescription Drug Affordability Board determined that its big-selling medication called Enbrel is unaffordable and began a process to ...

(Bloomberg) -- Amgen Inc.’s disclosed that US regulators paused the study of an early-stage obesity drug, a lucrative market the company is trying to crack. The Thousand Oaks, California-based ...

Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by ...

THOUSAND OAKS, Calif., Feb. 28, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the 45 th Annual TD Cowen Health Care Conference at 9:10 a.m. ET on Wednesday, March 5, 2025. Jay Bradner ...

Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical data and their pipeline priorities. CytomX signaled the EGFRxCD3 ...